Lisata Therapeutics (NASDAQ:LSTA) Stock Rating Reaffirmed by HC Wainwright

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued on Wednesday, Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 383.87% from the company’s previous close.

Lisata Therapeutics Trading Up 6.5 %

LSTA stock opened at $3.10 on Wednesday. The firm has a market cap of $25.75 million, a PE ratio of -1.26 and a beta of 1.21. Lisata Therapeutics has a 1 year low of $1.96 and a 1 year high of $3.83. The company has a fifty day simple moving average of $3.14 and a 200 day simple moving average of $3.11.

Lisata Therapeutics (NASDAQ:LSTA) last released its earnings results on Monday, August 12th. The company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.14. During the same quarter last year, the business posted ($0.50) EPS. As a group, analysts forecast that Lisata Therapeutics will post -2.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Lisata Therapeutics stock. Dimensional Fund Advisors LP raised its position in Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,336 shares of the company’s stock after acquiring an additional 5,639 shares during the period. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.